De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)
Articolo
Data di Pubblicazione:
2014
Citazione:
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) / F. Fabrizi, A. Aghemo, G. Moroni, P. Passerini, R. D'Ambrosio, P. Martin, P. Messa. - In: DIGESTIVE DISEASES AND SCIENCES. - ISSN 0163-2116. - 59:3(2014), pp. 691-695. [10.1007/s10620-013-2959-4]
Abstract:
HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
hepatitis C; interferon; membrano-proliferative glomerulonephritis; ribavirin; antiviral agents; drug therapy, combination; glomerulonephritis, membranoproliferative; hepatitis C, chronic; humans; interferon-alpha; male; middle aged; polyethylene glycols; recombinant proteins; ribavirin; gastroenterology; physiology
Elenco autori:
F. Fabrizi, A. Aghemo, G. Moroni, P. Passerini, R. D'Ambrosio, P. Martin, P. Messa
Link alla scheda completa: